Expert Advice 27 May 2020 Why Listening to Patient Organizations is Key in Drug Development As the biotech industry flourishes and therapies become more targeted and personalized, the need for drug developers to interact with patients is increasing as well. While patient organizations took a backseat in the past, they are continuously gaining importance in drug development today. Nowadays, talking with patient organizations has become paramount for successful drug development, […] May 27, 2020 - 11 minutesmins - By Larissa Warneck-Silvestrin Share WhatsApp Twitter Linkedin Email
News and Trends 26 May 2020 Argenx’s Rare Disease Treatment Strikes Gold in Phase III The Dutch biotech argenx aims to apply for FDA approval of its lead candidate efgartigimod after the first-in-class drug improved motor symptoms of the autoimmune disease myasthenia gravis in a phase III trial. The phase III trial tested the effect of efgartigimod in 167 patients with generalized myasthenia gravis. In this incurable chronic condition, the […] May 26, 2020 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
In Depth 25 May 2020 Could Cell Therapy Target the Symptoms of Severe Covid-19? The excessive inflammatory response seen in the most serious cases of Covid-19, along with shortages of ventilators, has caused a healthcare crisis in many countries around the world. Could cell therapy provide an answer to this dilemma? Most people who become infected with Covid-19 experience symptoms such as a dry cough and mild fever, and […] May 25, 2020 - 5 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 25 May 2020 Evonik and Beiersdorf Team Up to Turn CO₂ into Skin Care Products The German companies Evonik and Beiersdorf will work together on a joint research project to investigate how bacteria can be used to turn carbon dioxide (CO₂) and water into raw materials for skincare products. The process will be built on Evonik’s artificial photosynthesis technology – being developed independently of this project in collaboration with Siemens […] May 25, 2020 - 2 minutesmins - By Laura Cowen Share WhatsApp Twitter Linkedin Email
News and Trends 22 May 2020 Phase II Fail Ends Swiss-US Drug for Rare Kidney Disease An initially promising drug has failed to show benefits in a phase II trial for the rare kidney disease focal segmental glomerulosclerosis (FSGS), prompting the US biotech ChemoCentryx and its Swiss collaborator Vifor Pharma to drop it for this indication. Topline results from the phase II trial showed that 12 weeks of treatment with the […] May 22, 2020 - 2 minutesmins - By Anita Chakraverty Share WhatsApp Twitter Linkedin Email
Interview 21 May 2020 What 2019 Can Teach About European Biotech Investments Going Forward Following 2018’s bumper harvest for equity funding in European biotech, 2019 proved even more lucrative, particularly for private biotech companies. What are the biggest investment lessons learned from 2019, and how could Covid-19 change the dynamic in 2020? With the coronavirus pandemic thrusting global industry sectors into chaos, investors and entrepreneurs need to understand the […] May 21, 2020 - 9 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 20 May 2020 Phase II Success for Once-a-Day Eye Drops after Cataract Surgery A nanoparticle steroid therapy developed by Swiss biotech Oculis has reduced eye pain and inflammation in a phase II trial in cataract surgery patients. This is the second positive phase II this year for the company, which closed a €31M Series B fundraising round at the beginning of 2019. In February this year, Oculis also […] May 20, 2020 - 3 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 20 May 2020 Antibacterial Eliminates Recurrence of C. Difficile Infections in Phase II MGB Biopharma has reported positive results from a phase II trial showing that its antibacterial treatment for Clostridium difficile infections cured 100% of the patients, who showed no recurrence four weeks after. The bacterium Clostridium difficile causes life-threatening infections in the intestine and is the most common cause of diarrhea. Current treatments against it […] May 20, 2020 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 19 May 2020 Update: Novartis’ Gene Therapy Zolgensma Gets Nod from EU Update (19/05/2020): The gene therapy Zolgensma, developed by the big pharma Novartis and approved in the US last year, has received conditional approval in Europe for the treatment of spinal muscular atrophy (SMA). The gene therapy is approved to treat patients with a clinical diagnosis of SMA type 1 or SMA patients that have up […] May 19, 2020 - 5 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
In Depth 18 May 2020 Will Covid-19 Change the Face of Vaccine Development? The unprecedented scale of the current Covid-19 pandemic has led to a vaccine ‘race’ the like of which has never been seen before. This may change the face of vaccine development forever. Since the English physician Edward Jenner invented the first smallpox vaccine in 1796, vaccines have resulted in dramatic reductions in deaths from previously […] May 18, 2020 - 13 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 18 May 2020 Update: Spanish Food Startup Raises €12M to Grow Healthier Animal Fats Update (18/05/2020): Cubiq Foods has received a €5M investment from food technology investor Blue Horizon Ventures. With the funds, the startup aims to accelerate the production of its omega 3 fat additives based on cell culture, expecting to launch two products by the end of the year. 31/01/2019 Based in Barcelona, Cubiq Foods is developing […] May 18, 2020 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 15 May 2020 Affibody Signs €208M Deal To Market Autoimmune Drug in China Swedish biotech Affibody and Chinese firm Inmagene Biopharmaceuticals will work together to develop and commercialize Affibody’s phase II-stage drug for autoimmune diseases such as psoriasis. Under the agreement, Inmagene will commercialize Affibody’s treatment in the Greater China region and South Korea, as well as develop the drug in the Asia Pacific region excluding Japan. Meanwhile, […] May 15, 2020 - 3 minutesmins - By Laura Cowen Share WhatsApp Twitter Linkedin Email